secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-08-10T20:05:19+00:00
Accession:  0001193125-26-342334
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete
-------------------------------------------------------------------------

- Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).
- Cash, equivalents, and marketable securities totaled $461.1M as of June 30, 2026.
- Completed enrollment in Phase 3 OPERA-01 (palazestrant monotherapy); top-line data expected Q1 2027.
- Announced Bayer collaboration to study OP-3136 plus darolutamide in mCRPC; enrollment starts Q4 2026.
- Presented initial Phase 1 data for OP-3136 at ASCO 2026 showing tolerability and anti-tumor activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/0001193125-26-342334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer